Search results
Results From The WOW.Com Content Network
Rofecoxib (sold under the brand name Vioxx) was taken off the market in 2004 because of these concerns, while celecoxib (sold under the brand name Celebrex) and traditional NSAIDs received boxed warnings on their labels. Many COX-2–specific inhibitors have been removed from the US market.
Voluntarily withdrawn from US market because of risk of Progressive multifocal leukoencephalopathy (PML). Returned to market July 2006. Nefazodone: 2004 Europe, Australia, New Zealand and Canada [35] [36] [37] Branded version withdrawn by originator in several countries in 2007 for hepatotoxicity. Generic versions available. Still available in ...
Roman numerals: for example the word "six" in the clue might be used to indicate the letters VI; The name of a chemical element may be used to signify its symbol; e.g., W for tungsten; The days of the week; e.g., TH for Thursday; Country codes; e.g., "Switzerland" can indicate the letters CH; ICAO spelling alphabet: where Mike signifies M and ...
Daily Commuter crossword SUDOKU. Play the USA TODAY Sudoku Game. JUMBLE. Jumbles: AROSE TWICE WIZARD WHIMSY. Answer: If you can say "absent gone, removed, elsewhere, etc.", you have −"AWAY" WITH ...
William Mark Lanier (born October 20, 1960 [1]) is an American trial lawyer and founder and CEO of the Lanier Law Firm. He has led a number of high-profile product litigation suits resulting in billions of dollars in damages, including Johnson & Johnson baby powder and Merck & Co.'s Vioxx drug.
Nissen has led a number of inquiries as to the scientific integrity of many medications currently on the market. Starting with linked COX-2 inhibitors, such as Vioxx in 2001, Nissen was one of the first physicians to link it to an increased risk of heart attacks and strokes. Three years later Merck pulled Vioxx from the market when additional ...
Pepsi now has an 8.8 percent market share, just slightly edging out Diet Coke's market share of 8.5 percent for that second-place spot. Diet Coke had been at No. 2 since 2010, but a 6.6 percent ...
On April 7, 2005, Pfizer withdrew Bextra from the U.S. market on recommendation by the FDA, citing an increased risk of heart attack and stroke and also the risk of a serious, sometimes fatal, skin reaction. This was a result of recent attention to prescription NSAIDs, such as Merck's Vioxx.